Medicare Wegovy Use Rose After Approval for Heart Risk, but Remained Low (IMAGE)

University of Southern California

Medicare Wegovy Use Rose After Approval for Heart Risk, but Remained Low

Caption

Medicare fills of Wegovy increased nearly sevenfold in the six months after the weight-loss drug was approved to lower heart risk.

Credit

USC Schaeffer Center for Health Policy & Economics

Usage Restrictions

Must credt

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.